InotivNOTVQ -9.91% FCF Yield % is -3,911.49 as of Jun. 24, 2026. The stock has 4 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Inotiv ranks worse than 100% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Inotiv's Trailing 12-Month Free Cash Flow is $-13.6 Mil, and Market Cap is $0.3 Mil. Therefore, Inotiv's FCF Yield % for today is -3,911.49%.
The historical rank and industry rank for Inotiv's FCF Yield % or its related term are showing as below:
NOTVQ'
s FCF Yield % Range Over the Past 10 Years
Min: -5578.69 Med: -4.29 Max: 22.33
Current: -3911.49
During the past 13 years, the highest FCF Yield % of Inotiv was 22.33%. The lowest was -5578.69%. And the median was -4.29%.
NOTVQ's FCF Yield % is ranked worse than 100% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.65
vs NOTVQ: -3911.49
Inotiv's FCF Margin % for the quarter that ended in Mar. 2026 was -2.70%.
Inotiv FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Inotiv FCF Yield % Related Terms
Inotiv FCF Yield % Historical Data
* Premium members only.
The historical data trend for Inotiv's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Inotiv's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inotiv FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Inotiv's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inotiv (NOTVQ) has a FCF Yield % of -3,911.49 as of Jun. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Inotiv and its competitors. According to the industry distribution chart, Inotiv ranks #215 out of 215 companies in the Medical Diagnostics & Research industry.
Is Inotiv's FCF Yield % too high?
Inotiv's current FCF Yield % is -3,911.49. Based on the distribution chart, Inotiv ranks #215 out of 215 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Inotiv's FCF Yield % compare to NDRA and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Inotiv ranks #215 out of 215 companies for FCF Yield %. This places Inotiv in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Inotiv and its competitors. Inotiv's current FCF Yield % is -3,911.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (NOTVQ) is currently considered Possible Value Trap. The stock's GF Value™ is $1.68, compared to a current price of $0.01 — trading 99.4% below its estimated fair value. The current FCF Yield % is -3,911.49. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Inotiv (NOTVQ), the current FCF Yield % is -3,911.49 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NOTVQ has been successfully added to your 